Syndax Pharmaceuticals, Inc. Other Non-Current Assets
Syndax Pharmaceuticals, Inc. (SNDX) had Other Non-Current Assets of $0 as of 2024-12-31, per its 10-K filed 2025-03-03.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OtherAssetsNoncurrent · last filed 2025-03-03
- 2024-12-31: Other Assets, Noncurrent $0.00.
- 2024-09-30: Other Assets, Noncurrent $0.00.
- 2024-06-30: Other Assets, Noncurrent $156.00K.
- 2024-03-31: Other Assets, Noncurrent $248.00K.
| Period end | Other Assets, Noncurrent |
|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-03-03 |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-05 |
| 2024-06-30 | $156.00K 10-Q · filed 2024-08-01 |
| 2024-03-31 | $248.00K 10-Q · filed 2024-05-08 |
| 2023-12-31 | $463.00K 10-K · filed 2025-03-03 |
| 2023-09-30 | $587.00K 10-Q · filed 2023-11-02 |
| 2023-06-30 | $579.00K 10-Q · filed 2023-08-03 |
| 2023-03-31 | $693.00K 10-Q · filed 2023-05-08 |
| 2022-12-31 | $807.00K 10-K · filed 2024-02-27 |
| 2022-09-30 | $881.00K 10-Q · filed 2022-11-03 |
| 2022-06-30 | $995.00K 10-Q · filed 2022-08-08 |
| 2022-03-31 | $1.03M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $0.00 10-K · filed 2023-02-28 |
| 2021-03-31 | $115.00K 10-Q · filed 2021-05-11 |
| 2020-12-31 | $1.27M 10-K · filed 2022-03-01 |
| 2020-09-30 | $1.27M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $82.00K 10-Q · filed 2020-08-06 |
| 2020-03-31 | $82.00K 10-Q · filed 2020-05-07 |
| 2019-12-31 | $197.00K 10-K · filed 2021-03-12 |
| 2019-09-30 | $401.00K 10-Q · filed 2019-11-07 |
| 2019-06-30 | $201.00K 10-Q · filed 2019-08-07 |
| 2019-03-31 | $201.00K 10-Q · filed 2019-05-08 |
| 2018-12-31 | $219.00K 10-K · filed 2020-03-05 |
| 2018-09-30 | $225.00K 10-Q · filed 2018-11-05 |
| 2018-06-30 | $259.00K 10-Q · filed 2018-08-08 |
| 2018-03-31 | $229.00K 10-Q · filed 2018-05-09 |
| 2017-12-31 | $231.00K 10-K · filed 2019-03-07 |
| 2017-09-30 | $236.00K 10-Q · filed 2017-11-08 |
| 2017-06-30 | $239.00K 10-Q · filed 2017-08-10 |
| 2017-03-31 | $376.00K 10-Q · filed 2017-05-09 |
| 2016-12-31 | $243.00K 10-K · filed 2018-03-08 |
| 2016-09-30 | $179.00K 10-Q · filed 2016-11-14 |
| 2016-06-30 | $173.00K 10-Q · filed 2016-08-15 |
| 2016-03-31 | $217.00K 10-Q · filed 2016-05-16 |
| 2015-12-31 | $1.81M 10-K · filed 2017-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |